Free Trial

Leerink Partnrs Predicts DexCom's Q3 Earnings (NASDAQ:DXCM)

DexCom logo with Medical background

Key Points

  • Leerink Partners revised DexCom's Q3 2025 earnings per share (EPS) estimate down to $0.57, from the previous forecast of $0.63, while also projecting a full-year earnings estimate of $2.03 per share.
  • DexCom's latest quarterly earnings reported a net margin of 13.29% and a 15.2% increase in revenue year-over-year, surpassing previous expectations with $1.16 billion in revenue.
  • Institutional investors hold a significant 97.75% of DexCom's stock, indicating strong market confidence, with multiple analysts giving the stock a consensus rating of "Buy."
  • Interested in DexCom? Here are five stocks we like better.

DexCom, Inc. (NASDAQ:DXCM - Free Report) - Stock analysts at Leerink Partnrs decreased their Q3 2025 EPS estimates for DexCom in a research report issued to clients and investors on Wednesday, July 30th. Leerink Partnrs analyst M. Kratky now expects that the medical device company will earn $0.57 per share for the quarter, down from their previous forecast of $0.63. The consensus estimate for DexCom's current full-year earnings is $2.03 per share. Leerink Partnrs also issued estimates for DexCom's Q4 2025 earnings at $0.71 EPS, FY2025 earnings at $2.08 EPS and FY2026 earnings at $2.74 EPS.

Other research analysts also recently issued research reports about the stock. Robert W. Baird decreased their target price on shares of DexCom from $115.00 to $105.00 and set an "outperform" rating for the company in a research report on Friday, May 2nd. Citigroup reaffirmed a "buy" rating and issued a $102.00 target price (up previously from $82.00) on shares of DexCom in a research report on Thursday, May 22nd. Oppenheimer raised their target price on shares of DexCom from $95.00 to $102.00 and gave the company an "outperform" rating in a research report on Thursday. UBS Group raised their target price on shares of DexCom from $105.00 to $106.00 and gave the company a "buy" rating in a research report on Thursday. Finally, William Blair raised shares of DexCom to a "strong-buy" rating in a research report on Thursday. Four research analysts have rated the stock with a hold rating, fifteen have given a buy rating and four have issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Buy" and an average target price of $99.89.

Read Our Latest Stock Analysis on DXCM

DexCom Stock Down 1.8%

Shares of DXCM stock opened at $79.28 on Monday. The firm has a fifty day moving average of $84.57 and a 200-day moving average of $80.60. The company has a quick ratio of 1.35, a current ratio of 1.52 and a debt-to-equity ratio of 0.48. DexCom has a 12-month low of $57.52 and a 12-month high of $93.25. The company has a market capitalization of $31.09 billion, a price-to-earnings ratio of 55.06, a P/E/G ratio of 1.66 and a beta of 1.43.

DexCom (NASDAQ:DXCM - Get Free Report) last issued its quarterly earnings data on Wednesday, July 30th. The medical device company reported $0.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.45 by $0.03. DexCom had a net margin of 13.29% and a return on equity of 30.41%. The company had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.13 billion. During the same quarter in the prior year, the firm earned $0.43 earnings per share. The firm's revenue was up 15.2% compared to the same quarter last year.

Insider Activity at DexCom

In other news, Director Mark G. Foletta sold 2,750 shares of the firm's stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $83.13, for a total transaction of $228,607.50. Following the completion of the sale, the director owned 56,621 shares in the company, valued at approximately $4,706,903.73. This trade represents a 4.63% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Michael Jon Brown sold 500 shares of the firm's stock in a transaction dated Monday, June 16th. The stock was sold at an average price of $82.80, for a total transaction of $41,400.00. Following the sale, the executive vice president owned 95,102 shares of the company's stock, valued at approximately $7,874,445.60. This represents a 0.52% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 28,656 shares of company stock worth $2,412,191. 0.32% of the stock is owned by corporate insiders.

Institutional Trading of DexCom

A number of hedge funds have recently modified their holdings of the stock. Brighton Jones LLC raised its stake in DexCom by 257.7% in the 4th quarter. Brighton Jones LLC now owns 16,582 shares of the medical device company's stock worth $1,290,000 after purchasing an additional 11,946 shares in the last quarter. Bank Pictet & Cie Europe AG raised its stake in DexCom by 1.8% in the 4th quarter. Bank Pictet & Cie Europe AG now owns 111,063 shares of the medical device company's stock worth $8,637,000 after purchasing an additional 2,010 shares in the last quarter. O Shaughnessy Asset Management LLC raised its stake in DexCom by 16.9% in the 4th quarter. O Shaughnessy Asset Management LLC now owns 13,384 shares of the medical device company's stock worth $1,041,000 after purchasing an additional 1,930 shares in the last quarter. Alliancebernstein L.P. raised its stake in DexCom by 24.1% in the 4th quarter. Alliancebernstein L.P. now owns 555,164 shares of the medical device company's stock worth $43,175,000 after purchasing an additional 107,916 shares in the last quarter. Finally, Huntington National Bank raised its stake in DexCom by 94.5% in the 4th quarter. Huntington National Bank now owns 2,748 shares of the medical device company's stock worth $214,000 after purchasing an additional 1,335 shares in the last quarter. Institutional investors and hedge funds own 97.75% of the company's stock.

About DexCom

(Get Free Report)

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

Read More

Earnings History and Estimates for DexCom (NASDAQ:DXCM)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in DexCom Right Now?

Before you consider DexCom, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DexCom wasn't on the list.

While DexCom currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Palantir & AMD Earnings: Massive Options Setups Ahead
3 Value Plays Set to Explode
5 Stocks to BUY NOW in August 2025

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines